Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws
TORONTO, ON / ACCESSWIRE / December 22, 2020 / Further to the July 5, 2020, November 17, 2020 and November 23, 2020 press releases issued by Novamind Inc. (formerly Hinterland Metals Inc.) (the “Company“) and Novamind Ventures Inc. (“Novamind“, and together with the Company, the “Parties“), the Parties are pleased to announce that they have received conditional approval from the Canadian Securities Exchange (the “CSE“) for listing of the common shares of the Company (the “Common Shares“) following the completion of the previously announced reverse takeover transaction (the “Transaction“) with Novamind. The Parties will carry on the business of Novamind, a leading mental health company specialized in psychedelic-assisted psychotherapy.
Subject to final CSE approval, the Common Shares of the Company are expected to commence trading on the CSE under the ticker “NM” on or about January 5, 2021.
Novamind shareholders will receive their Common Shares by email in the form of Direct Registration System (“DRS“) statements that can be deposited for trading. The DRS statements are expected to be emailed to all Novamind shareholders no later than December 24, 2020.
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly-owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit www.novamind.ca.
About the Company
The Company is an unlisted Canadian public company, reporting in the provinces of British Columbia, Alberta and Quebec.
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512
Bill Mitoulas, Investor Relations
None of the securities to be issued pursuant to the Transaction have been or will be registered under the United States Securities Act of 1933, as amended, or any state securities laws, and any securities issued pursuant to the Transaction are anticipated to be issued in reliance upon available exemptions from such registration requirements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities.
Completion of the Transaction is subject to a number of conditions. There can be no assurance that the Transaction will be completed as proposed or at all.
Investors are cautioned that, except as disclosed in the Listing Statement (or other disclosure documents to be prepared by the Parties) to be prepared in connection with the Transaction, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of the Company or Novamind should be considered highly speculative.
The CSE has not in any way passed upon the merits of the Transaction and have neither approved nor disapproved the contents of this press release. Approval of the CSE for the listing of the Common Shares will be subject to, among other things, satisfying the listing requirements of the CSE. There can be no assurance that the approval of the CSE regarding the listing of the Common Shares will be obtained.
All information contained in this news release with respect to Novamind and the Company was supplied by the parties, respectively, for inclusion herein, and each parties’ directors and officers have relied on each other for any information concerning such party.
This news release contains forward-looking statements relating to the timing and completion of the Transaction and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of Novamind and the Company include the failure to satisfy the conditions to completion of the Transaction set forth above and other risks detailed from time to time in the filings made by the Parties under securities regulations.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Parties. As a result, the Parties cannot guarantee that the Transaction will be completed on the terms and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Parties will only update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.SOURCE: Novamind Inc.